Investigating biomarkers for early prediction of bronchopulmonary dysplasia in preterm infants
The Role of Volatile Organic Compounds (VOCs), Airway Mucins and Microbiome in the Development of Bronchopulmonary Dysplasia and the Feasibility of Exhaled Breath VOCs Analysis as an Early Detection Tool
This study is trying to find early signs that can help predict if premature babies will develop bronchopulmonary dysplasia, using samples from their breath, throat, and placenta.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 140 (estimated) |
| Ages | 0 Days to 3 Days |
| Sex | All |
| Sponsor | University Hospital, Antwerp Academic / other |
| Locations | 1 site (Edegem, Antwerp) |
| Trial ID | NCT06342752 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify early biomarkers associated with bronchopulmonary dysplasia (BPD) in infants born at less than 30 weeks gestational age. Researchers will collect various samples, including breath, throat swabs, and placental samples, to analyze volatile organic compounds, airway mucins, and the microbiome. The study will monitor infants for the development of BPD, diagnosed at 36 weeks postmenstrual age based on respiratory support needs. Follow-up visits at 6 and 12 months will assess lung function and microbiome composition.
Who should consider this trial
Good fit: Ideal candidates for this study are infants born at a gestational age of less than 30 weeks.
Not a fit: Patients with major congenital defects or unstable conditions as determined by their neonatologist may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier identification and targeted interventions for infants at risk of developing BPD, potentially improving outcomes.
How similar studies have performed: While the approach of using biomarkers for early prediction of BPD is promising, it remains largely novel and untested in this specific context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Born at a gestational age \< 30 weeks Exclusion Criteria: * Major congenital defect or disorder * Patients with an unstable general condition as deemed by the attending neonatologist
Where this trial is running
Edegem, Antwerp
- University Hospital Antwerp — Edegem, Antwerp, Belgium (Recruiting)
Study contacts
- Principal investigator: Antonius Mulder, MD, PhD,prof — University Hospital Antwerp, Belgium
- Study coordinator: Inès Ghys, MD
- Email: ines.ghys@uantwerpen.be
- Phone: +3232655230
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.